Fat Loss & Body Composition

Investigational triple-agonist with the largest weight-loss numbers in early trials.

The visceral-fat peptide — FDA-approved for HIV-associated lipodystrophy.

Non-peptide oral weight-loss agent with strong Phase 2 data.

Aggressive research peptide that induces fat-cell apoptosis via vascular targeting.

NNMT inhibitor for fat loss and metabolic health.

GH-fragment with lipolytic action and no growth signaling.

Long-acting GHRH analog dosed weekly, distinct from the no-DAC version.

Oral GH secretagogue with robust human data on GH and IGF-1 elevation.

Recombinant human growth hormone itself, the molecule the secretagogues chase.

Antibody that builds muscle while cutting fat, a recomposition play.

Vascular-targeting fat-loss prodrug, potent but carries real toxicity concerns.

Preclinical exercise mimetic that boosts fat oxidation and endurance.

Endurance and fat-loss compound popular despite serious safety concerns.

AMPK activator studied as an exercise mimetic for endurance and fat use.

MC4R agonist approved for specific genetic forms of obesity.

Less-studied cousin of 5-Amino-1MQ, marketed for body-composition support.

Clean GH pulse — widely used for sleep, recovery, and lean composition.

Mitochondrial peptide for metabolic flexibility and exercise capacity.

Pre-clinical 'exercise in a bottle' candidate — improves endurance and metabolic flexibility in animal models.

Original 'exercise-mimetic' research compound. WADA-prohibited in sport.

Strong GH release with modest cortisol elevation — older but effective.

Sister compound to AOD-9604 — niche fat-loss tool with modest data.

Mitochondrial fat-shuttle cofactor — used for endurance support and recomposition protocols.

Natural parent of melanotan-class peptides.

Aesthetic-clinic 'fat-dissolve' injection marketed for small stubborn pockets.

The 'bonding' peptide — also has modest appetite and stress effects.

Classic medspa 'fat-burner shot' — lipotropic amino acids plus B-vitamins.